Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × mCRPC × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 110 Prostatic Neoplasms 87 Carcinoma, Non-Small-Cell Lung 86 Neoplasms 64 Multiple Myeloma 57 Lung Neoplasms 52 Melanoma 45 Ovarian Neoplasms 39 Leukemia, Myeloid, Acute 39 Colorectal Neoplasms 39 Leukemia, Lymphocytic, Chronic, B-Cell 35 Neoplasm Metastasis 34 Brain Neoplasms 32 Lymphoma 31 Pancreatic Neoplasms 28 Glioma 28 Lymphoma, Non-Hodgkin 27 Glioblastoma 27 Carcinoma, Renal Cell 24 Urinary Bladder Neoplasms 23 Squamous Cell Carcinoma of Head and Neck 21 Carcinoma, Hepatocellular 21 Uterine Cervical Neoplasms 20 Lymphoma, Follicular 20 Triple Negative Breast Neoplasms 18 Myelodysplastic Syndromes 18 Fallopian Tube Neoplasms 18 Recurrence 17 Hematologic Neoplasms 17 Lymphoma, Large B-Cell, Diffuse 16

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡